Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
A new underground industry has emerged where people are buying raw compounds for Ozempic, Botox, filler and skin-tightening treatments directly from Chinese suppliers — and injecting them at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback